These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24590932)

  • 1. Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009.
    Goldman DP; Juday T; Seekins D; Linthicum MT; Romley JA
    Health Aff (Millwood); 2014 Mar; 33(3):362-9. PubMed ID: 24590932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early HIV treatment led to life expectancy gains valued at $80 billion for people infected in 1996-2009.
    Romley JA; Juday T; Solomon MD; Seekins D; Brookmeyer R; Goldman DP
    Health Aff (Millwood); 2014 Mar; 33(3):370-7. PubMed ID: 24590933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.
    Sempa J; Ssennono M; Kuznik A; Lamorde M; Sowinski S; Semeere A; Hermans S; Castelnuovo B; Manabe YC
    BMC Public Health; 2012 Sep; 12():736. PubMed ID: 22943068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
    Schackman BR; Freedberg KA; Weinstein MC; Sax PE; Losina E; Zhang H; Goldie SJ
    Arch Intern Med; 2002 Nov; 162(21):2478-86. PubMed ID: 12437408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis.
    Ciaranello AL; Myer L; Kelly K; Christensen S; Daskilewicz K; Doherty K; Bekker LG; Hou T; Wood R; Francke JA; Wools-Kaloustian K; Freedberg KA; Walensky RP
    PLoS One; 2015; 10(3):e0117751. PubMed ID: 25756498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.
    Losina E; Schackman BR; Sadownik SN; Gebo KA; Walensky RP; Chiosi JJ; Weinstein MC; Hicks PL; Aaronson WH; Moore RD; Paltiel AD; Freedberg KA
    Clin Infect Dis; 2009 Nov; 49(10):1570-8. PubMed ID: 19845472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
    Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
    Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.
    Franke MF; Robins JM; Mugabo J; Kaigamba F; Cain LE; Fleming JG; Murray MB
    PLoS Med; 2011 May; 8(5):e1001029. PubMed ID: 21559327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study.
    Balagopal A; Asmuth DM; Yang WT; Campbell TB; Gupte N; Smeaton L; Kanyama C; Grinsztejn B; Santos B; Supparatpinyo K; Badal-Faesen S; Lama JR; Lalloo UG; Zulu F; Pawar JS; Riviere C; Kumarasamy N; Hakim J; Li XD; Pollard RB; Semba RD; Thomas DL; Bollinger RC; Gupta A;
    J Acquir Immune Defic Syndr; 2015 Oct; 70(2):163-71. PubMed ID: 26017661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.
    Granich R; Kahn JG; Bennett R; Holmes CB; Garg N; Serenata C; Sabin ML; Makhlouf-Obermeyer C; De Filippo Mack C; Williams P; Jones L; Smyth C; Kutch KA; Ying-Ru L; Vitoria M; Souteyrand Y; Crowley S; Korenromp EL; Williams BG
    PLoS One; 2012; 7(2):e30216. PubMed ID: 22348000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.